Item 9 Labs (Item 9 Labs) Additional Paid-In Capital : $143.69 Mil(As of Jun. 2023)

View and export this data going back to 2011. Start your Free Trial

What is Item 9 Labs Additional Paid-In Capital?

Item 9 Labs's quarterly additional paid-in capital increased from Dec. 2022 ($142.08 Mil) to Mar. 2023 ($142.81 Mil) and increased from Mar. 2023 ($142.81 Mil) to Jun. 2023 ($143.69 Mil).

Item 9 Labs's annual additional paid-in capital increased from Sep. 2020 ($44.43 Mil) to Sep. 2021 ($133.42 Mil) and increased from Sep. 2021 ($133.42 Mil) to Sep. 2022 ($140.42 Mil).

Item 9 Labs Additional Paid-In Capital Historical Data

The historical data trend for Item 9 Labs's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Item 9 Labs Additional Paid-In Capital Chart

Item 9 Labs Annual Data

Trend

Sep13

Sep14

Sep15

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Additional Paid-In Capital

Get a 7-Day Free Trial

3.44

18.15

44.43

133.42

140.42

Item 9 Labs Quarterly Data
	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23
Additional Paid-In Capital	Get a 7-Day Free Trial															138.50	140.42	142.08	142.81	143.69

Item 9 Labs Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

Item 9 Labs Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Item 9 Labs's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Item 9 Labs (Item 9 Labs) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Item 9 Labs Corp (OTCPK:INLB) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

N/A

Address

2111 E. Highland Avenue, Suite B375, Phoenix, AZ, USA, 85016

Website

https://www.item9labscorp.com

Item 9 Labs Corp is a vertically integrated cannabis operator and dispensary franchisor delivering premium products from its large-scale cultivation and production facilities in the United States. The Item 9 Labs brand specializes in products and user experience across several cannabis categories. The company also offers a dispensary franchise model through the national Unity Rd. retail brand. Easing barriers to entry, the franchise provides an opportunity for both new and existing dispensary owners to leverage the knowledge, resources, and ongoing support needed to thrive in their state compliantly and successfully. It also brings industry practices to markets nationwide through distinctive retail experience, cultivation capabilities, and product innovation.

Executives

Taylor Lawrence X. Iii	director	2727 N 3RD STREET, SUITE 201, PHOENIX AZ 85004
Eric Kutscher	director	2727 N 3RD STREET, SUITE 201, PHOENIX AZ 85004
Michael P Keskey	director	C/O ITEM 9 LABS, 2727 N. 3RD STREET, SUITE 201, PHOENIX AZ 85004
Douglas P Bowden	director	C/O ITEM 9 LABS 2727 N. 3RD STREET., SUITE 201, PHOENIX AZ 85004
Christopher Leland Wolven	officer: Chief Operating Officer	5743 N 19TH ST, PHOENIX AZ 85016
Sara Gullickson	director, officer: Chief Executive Officer	1709 BETHANY RD, PHOENIX AZ 85016
Andrew Douglas Bowden	director	3621 N 39TH ST, PHOENIX AZ 85018
Robert E Mikkelsen	officer: CFO, Secretary, Treasurer	2033 N OVERFIELD RD, CASA GRANDE AZ 85194
Patrick Sean Dugan	10 percent owner	2033 N OVERFIELD RD, CASA GRANDE AZ 85194
Andrew Poirier	10 percent owner	1946 E RANCHO DR, PHOENIX AZ 85016
Bryce Skalla	director, officer: President	2033 N OVERFIELD RD, CASA GRANDE AZ 85194
Cohen Daniel E Md	director, officer: President	10035 GRISTMILL RIDGE, EDEN PRAIRIE MN 55347
Hayjour Family Limited Partnership	director, officer: President & CEO	10799 N 90TH STREET, SUITE 200, SCOTTSDALE AZ 85260
Jessica L Smith	officer: CFO, Secretary, Treasurer	8399 E. INDIAN SCHOOL RD., SUITE 202, SCOTTSDALE AZ 85251
Lorrie Henderson	officer: Chief Operating Officer	8399 E INDIAN SCHOOL RD, SUITE 202, SCOTTSDALE AZ 85251